Inhibition of Spinal Oxidative Stress by Bergamot Polyphenolic Fraction Attenuates the Development of Morphine Induced Tolerance and Hyperalgesia in Mice

Filomena Lauro¹, Luigi Antonio Giancotti¹, Sara Ilari¹, Concetta Dagostino²,³, Micaela Gliozzi⁴, Chiara Morabito⁵, Valentina Malafoglia⁶, William Raffaeli⁶, Maurizio Muraca⁵, Bianca M. Goffredo⁷, Vincenzo Mollace⁴, Carolina Muscoli⁴*

¹ San Raffaele Roma S.r.l., Roccella di Borgia, Catanzaro, Italy, ² Department of Surgical Sciences, Parma University, Parma, Italy, ³ YAP (Young Against Pain) Collaboration, Parma, Italy, ⁴ Institute of Research for Food Safety & Health (IRC_FSH), Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy, ⁵ Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy, ⁶ Institute for Research on Pain, ISAL-Foundation, Torre Pedrera (RN), Italy, ⁷ Research Laboratories, Children’s Hospital “Bambino Gesù” Research Institute, Rome, Italy

* muscoli@unicz.it

Abstract

Citrus Bergamia Risso, commonly known as Bergamot, is a fruit whose Essential Oil and Bergamot Polyphenolic Fraction have numerous medicinal properties. It is also an excellent antioxidant and in this study, for the first time, its potential effect on morphine induced tolerance in mice has been investigated. Our studies revealed that development of antinociceptive tolerance to repeated doses of morphine in mice is consistently associated with increased formation of superoxide, malondialdehyde and tyrosine-nitrated proteins in the dorsal horn of the spinal cord such as the enzyme glutamine synthase. Nitration of this protein is intimately linked to inactivation of its biological function and resulting increase of glutamate levels in the spinal cord. Administration of Bergamot Polyphenolic Fraction (5–50 mg/kg) attenuated tolerance development. This effect was accompanied by reduction of superoxide and malondialdehyde production, prevention of GS nitration, re-establishment of its activity and of glutamate levels. Our studies confirmed the main role of free radicals during the cascade of events induced by prolonged morphine treatment and the co-administration of natural derivatives antioxidant such as Bergamot Polyphenolic Fraction can be an important therapeutic approach to restore opioids analgesic efficacy.

Introduction

For centuries, opioid drugs have been the mainstay of pain treatment [1], but long-term morphine administration leads to analgesic tolerance [2]. Tolerance to the analgesic effects of opiates results from the complex changes in various molecular and biochemical pathways [3].
Numerous data have demonstrated the involvement of superoxide (SO, $O_2^-$) and peroxynitrite (PN, ONOO-) (the product of the diffusion-controlled reaction of SO with nitric oxide, NO) in the development of chronic pain, in the transition of acute to chronic pain as well as in the opiate-induced hyperalgesia and antinociceptive tolerance. Peroxynitrite is considered the major agent responsible for tyrosine-nitration proteins in the dorsal horn of the spinal cord, including the mitochondrial isoform of superoxide dismutase (MnSOD), the glutamate transporter GLT-1, the glutamate receptor NMDA (N-methyl-D-aspartate) and the enzyme glutamine synthase (GS) [4, 5]. Furthermore, antinociceptive tolerance and PN production have been associated with activation of spinal cord glial cells, as well as production of pro-inflammatory cytokines such as TNF-$\alpha$, IL-1$\beta$ and IL-6 and spinal sensitization and activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) [4, 6].

Bergamot (Citrus bergamia, Rissu) is an endemic plant of the Calabrian region in Southern Italy with a unique profile of flavonoid and flavonoid glycosides present in its juice and albedo, such as neoeriocitrin, neohesperidin, naringin, rutin, neodesmin, rhoifolin and poncirin. Bergamot differs from other citrus fruits not only because of the composition of its flavonoids, but also because of their particularly high concentration [7]. It is used in cosmetics and food, but it has also numerous medicinal properties: bergamot peel is a potential source of natural antimicrobials that are active against Gram-negative bacteria [8], and in vapour form has been shown to have antimicrobial effects against both bacteria and fungi [9]; Bergamot Essential Oil (BEO) has also a neuroprotective function, in fact it reduces neuronal damage caused in vitro by excitotoxic stimuli and this neuroprotective effect was associated with prevention of injury-induced engagement of critical death pathways [10]. Bergamot polyphenols have hypolipemic and hypoglycaemic activity: given orally for 30 days to both rats and patients reduces total cholesterol, LDL (an effect also accompanied by elevation of cHDL) and triglyceride levels [7]. Furthermore, in a model of carotid arteries injured by balloon angioplasty, balloon injury led to a significant restenosis with smooth muscle cell proliferation and neointima formation, accompanied by increased expression of LOX-1 receptor, malondialdehyde, superoxide formation and nitrotyrosine staining. Pretreatment of rats with BEO-NVF (nonvolatile fraction) reduced the neointima proliferation, LOX-1 expression, MDA overproduction, nitrotyrosine staining and in situ ROS generation in a dose-dependent manner [11].

This data evidenced as bergamot extract is an excellent antioxidant, in fact it exhibited 100% antioxidant activity in the aldehyde/carboxylic acid assay [12]. In particular, bergamot polyphenols are contained mainly in the albedo of the bergamot fruit, thereby getting high concentrations in bergamot juice after the fruit is squeezed [7]. In this study, we evaluated the ability of BPF (Bergamot Polyphenolic Fraction) to inhibit tolerance induced by morphine-repeated administration. Our data showed for the first time, that co-administration of morphine and BPF can be a good therapeutic approach for the treatment of chronic pain thanks to its ability to inhibit, in a dose-dependent manner, the development of tolerance preserving analgesic-morphine property.

Materials and Methods

Animals

Male CD-1 mice (24–30 g; Charles River Laboratory) were housed and cared for in accordance with the guidelines of the University of Tor Vergata, Rome, Italy, as well as complied with the Italian regulations for the protection of animals used for experimental and other scientific purposes, and with European Economic Community regulations (2010/63/UE). The study was approved by Italian Ministry of Health (permit number 144/2012-B). Mice were housed 5–7 per cage and maintained under identical conditions of temperature (21 ± 1°C) and humidity.
with a 12-hour light/12-hour dark cycle and allowed food ad libitum. Natural antioxidant BPF was kindly provided by H&AD (Herbal and Antioxidants Derivatives srl). All other drugs were purchased from Sigma and dissolved in saline (sodium chloride 0.9%). The following experimental groups were used:

**Acute morphine groups.** Mice received a single s.c. injection of morphine (1, 3, 6 mg/kg, n = 15 each dose). Behavioral tests have been carried out after 30, 45, 60 minutes from the treatment.

**Naive group.** In this group, mice (n = 15) were injected twice a day with an i.p. injection of saline (vehicle used to deliver the drugs to the other groups over 4 days) and a s.c. injection of saline (vehicle used to deliver morphine to the other groups over 4 days). On day 5 mice received an i.p. injection of saline followed 15 minutes later by a s.c. injection of morphine (3 mg/kg).

**BPF group.** In this group, mice (n = 15) were injected twice a day for 5 days with an i.p. injection of the highest dose of BPF (50 mg/kg) followed by s.c. injection of saline.

**Morphine group.** In this group, mice (n = 15) were injected twice a day for 4 days with an i.p. injection of saline and a s.c. injection of morphine (20 mg/kg). On day 5 mice received an i.p. injection of saline followed 15 minutes later by a s.c. dose of acute morphine (3 mg/kg).

**Morphine plus drug groups.** In this group, mice (n = 15) were injected twice a day for 4 days with an i.p. injection of different doses of BPF (5, 25 and 50 mg/kg), L-NAME (10 mg/kg) and MnTBAP (10 mg/kg) followed by s.c. injection of morphine (20 mg/kg). On day 5 mice received an i.p. dose of drugs, followed 15 minutes later by the s.c. dose of acute morphine (3 mg/kg).

All doses were given in a 0.1 ml volume at approximately 7 am and 4 pm.

On day 5 and after the behavioral tests, carried out after 60 minutes from the treatment, the animals were euthanized via decapitation with a guillotine assuring that discomfort and pain to animals was limited to that which was unavoidable for the conduct of scientifically valuable research. Spinal cord tissues from the lumbar enlargement segment of the spinal cord (L4–L5) were removed and tissues stored at -80°C for subsequent analysis.

**Hot plate test**

Nociceptive thresholds were determined by measuring latencies (in seconds) of mice placed in a transparent glass cylinder on a hot plate (Panlab) maintained at 52°C. Determination of antinociception was assessed between 7:00 am and 10:00 am. Responses indicative of nociception included intermittent lifting and/or licking of the hindpaws or escape behavior. Hot plate latencies were taken in mice from all groups on day 5 before (baseline latency) and 50 minutes after an acute dose of morphine (3 mg/kg). A cut-off latency of 25 seconds was employed to prevent tissue damage. 15 mice per group were used, and all experiments were conducted with the experimenters blinded to treatment conditions. Results are expressed as percentage of maximum possible antinociceptive effect, which was calculated as follows: (response latency − baseline latency) / (cut-off latency − baseline latency) × 100.

**In situ detection of superoxide anion**

Detection of superoxide anion was evaluated by hydroethidine (HE) administration. 50 min after challenge dose of morphine administration mice were treated with 200μl of PBS containing 1μg/μl of hydroethidine (Molecular Probes) and 1% dimethylsulfoxide (DMSO). Spinal cords were removed 15 min later and frozen in nitrogen. Sections of 5 μm were cut by a cryostat and examined by fluorescence microscope (excitation 510nm, emission 580) for the evaluation of ethidium bromide accumulation, the oxidation product of hydroethidine.
Immunoprecipitation and Western blot analyses

Dorsal half of the spinal cord lumbar region enlargement (L4–L5) were obtained as described previously [13, 14, 15]. The resulting lysates samples were stored immediately at –80°C and immunoprecipitation of tyrosine nitrated protein followed by Western blot analysis performed as previously described [13, 14]. For immunoprecipitation of nitrated proteins, a well-characterized affinity-purified anti-nitrotyrosine monoclonal antibody conjugated to agarose beads from Upstate Biotechnology was used according to the manufacturer’s instructions. To determine whether GS was nitrated, Western blot analysis of i.p. protein complex and total lysates were performed using antibodies specific to these proteins. Briefly, the immunoprecipitated proteins were resolved in 10% SDS-PAGE mini and proteins transferred to nitrocellulose membranes. Membranes were blocked for 2 hours at room temperature with 5% BSA in TBST 0.1%, followed by overnight incubation with monoclonal antibody for GS (1:1000; Cayman Chemical). Membranes were then washed with TBS/T and incubated secondary antibodies conjugated to peroxidase for 1 hour at room temperature. After washes, protein bands were visualized by enhanced chemiluminescence (Amersham Biosciences). After stripping, total lysates membranes were reprobed with either monoclonal anti β-actin antibody (1:2000; Sigma-Aldrich) as a loading control. The relative expression of the protein levels as the band density for GS (45 kDa) and β-actin (50 kDa) were quantified by scanning of the X-ray films with MSF-300G and a computer program.

Malondialdehyde detection

MDA quantification was performed through thiobarbituric acid reactive substances (TBARS) assay. In brief, tissue sample were added to a vial containing 10% NaOH, 20% Acetic Acid and TBA. The vials were boiled at 90–100°C and after 1h the tubes were placed in ice to stop reaction. Before being transferred to a black 96-well microtiter plate samples were centrifugated 10 minutes at 1600 x g at 4°C. The MDA-TBA adduct was measured fluorometrically at an excitation wavelength of 530 nm and emission wavelength of 550 nm using Infinite 200 microplate fluorometer (Tecan).

Analysis of spinal cord amino acids

Dorsal half of the spinal cord lumbar region enlargement (L4–L5) were washed with 0.15 M NaCl, weighed and homogenized at 4°C with cold PBS. Subsequently was added 5% salicylic acid and kept at RT for 15 minutes. Homogenated was centrifuged at 11.000 g for 15 minutes at 4°C and supernatant was stored at 20°C for the subsequent HPLC analysis.

Statistical analysis

Results are given as mean ± SEM. Statistical analysis was performed using ANOVA followed by Student-Newman-Keuls. P<0.05 was considered statistically significant.

Results

The development of morphine-induced tolerance is inhibited by antioxidant

Acute injection of morphine (3 mg/kg), in animal that received saline over 4 days (vehicle group), produced a significant near-maximal antinociceptive response until 60 minutes after administration (Figs 1 and 2) compared with animals receiving an equivalent injection of saline (naive group).
Repeated morphine administrations over the same time course (morphine group) led to the development of antinociceptive tolerance, as evidenced by a significant loss of its antinociceptive response (Fig 2). Tolerance is associated to superoxide production in the L4-L5 portion of the spinal cord (Fig 3). To investigate whether the increased superoxide synthesis had a functional role in the development of morphine antinociceptive tolerance, morphine was co-administered with antioxidants such as BPF (Table 1). Co-administration of morphine with BPF inhibited in a dose-dependent manner (5–50 mg/kg/d, n = 15) the development of antinociceptive tolerance (Fig 2). To confirm the important antioxidant effect of BPF in the morphine tolerance, we compared BPF action with L-NAME, a nonselective NOS inhibitor N-nitro-L-arginine methyl ester, and MnTBAP, the nonselective O$_2^-$ scavenging agent. The effect of L-NAME or MnTBAP was similar to BPF and no significant difference have been observed in the capacity of inhibiting the development of morphine tolerance antinociceptive (Fig 2B). In naïve mice, the highest dose of BPF (50 mg/kg) not influenced the response to

![Fig 1. Morphine dose-response curve analysis.](image1)

Fig 1. Morphine dose-response curve analysis. Acute injection of morphine (3 mg/kg), in mice, produced a significant near-maximal antinociceptive response until 60 minutes. Results are expressed as mean ± SEM for 15 mice; *P<0.001 vs morphine 0 mg/kg.

![Fig 2. The development of morphine antinociceptive tolerance is prevented by substances with antioxidant properties.](image2)

Fig 2. The development of morphine antinociceptive tolerance is prevented by substances with antioxidant properties. (A-B) A significant loss to the antinociceptive effect of the acute injection of morphine was observed in animals that received repeated administration of morphine over 4 days. (A) Co-administration of morphine over 4 days with BPF (5–50 mg/kg) inhibited the development of tolerance in a dose-dependent manner. When tested alone, the highest dose of BPF (50 mg/kg) did not have antinociceptive effects. (B) In morphine-treated mice, the effect of BPF (25 mg/kg) was comparable to L-NAME (10 mg/kg) or MnTBAP (10 mg/kg). Results are expressed as mean ± SEM for 15 mice. *P<0.001 vs Naive; †P<0.01 vs morphine; ††P<0.001 vs morphine.
acute morphine dose (3 mg/kg) excluding an interaction between morphine and antioxidants. When tested alone at the highest dose, L-NAME (10 mg/kg) and MnTBAP (10 mg/kg) [4, 17] BPF (Fig 2A), did not have antinociceptive effects evaluated with hot plate test (range 6/7 seconds).

**BPF inhibits superoxide and MDA increase in morphine-tolerant mice**

Hydroethidine (HE), when oxidized by superoxide, forms the fluorescent cation ethidium [18, 19], the presence of the fluorescent probe evidenced superoxide production. Our data demonstrated that chronic morphine administration induced an increase of superoxide production as showed by the presence of ethidium (Fig 3). Furthermore, to confirm the formation of radical species during morphine tolerance, we quantified a well-known oxidative stress marker, the

---

**Fig 3. Chronic morphine administration is associated with increased superoxide formation in the L4-L5 portion of spinal cord.** Chronic morphine administration induced an overproduction of O$_2^-$ in the spinal cord compared with mice naïve group as demonstrated by HE oxidation. BPF (25 mg/kg; n = 15) or MnTBAP (10 mg/kg) co-administration was able to reduce O$_2^-$ chronic morphine-induced increase. Original magnification, ×10. Micrographs are representative of at least 3 from different animals in experiments performed on different days.

doi:10.1371/journal.pone.0156039.g003
malondialdehyde (MDA), a highly reactive three carbon dialdehyde produced as a byproduct of polyunsaturated fatty acid peroxidation and arachidonic acid metabolism. Prolonged morphine treatment induced an increase of MDA level (Fig 4) evaluated through MDA-TBA assay. Co-administration of morphine with BPF or MnTPAB for over 4 days inhibited antinociceptive tolerance to morphine (Fig 2) together with superoxide formation (Fig 3) and MDA levels (Fig 4). Therefore, acute morphine administration, in naïve animals, had not showed a significant ethidium production (Fig 3).

Table 1. Bergamot polyphenolic fraction components.

| Component                                      |
|------------------------------------------------|
| Apigenin-6-8-di-C-glucoside                    |
| Diosmetin-6-8-di-C-glucoside                   |
| Luteolin-6-8-di-C-glucoside                    |
| Diosmetin-8-C-glucoside                        |
| Diosmetin-7-O-glucoside                        |
| 4H-1-Benzopyran-4-one, 7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl) |
| Luteolin-7-O-neohesperidoside                  |
| Rhoifolin                                      |
| Neodiosmin                                     |
| Diosmetin-7-O-neohesperidoside-6′-O-HMG        |
| Apigenin-7-O-neohesperidoside-6′-O-HMG         |
| Esperetin-7-O-glucoside                        |
| Neoesperidin                                   |
| Naringin                                       |
| Neoequorsinil                                  |
| Eriodictyol-7-O-neohesperidoside-6′′-O-HMG     |
| Bruteridin                                     |
| Melitidin                                      |
| Hesperetin-7-O-glucoside-6′-O-HMG              |
| Naringenin-7-O-glucoside-6′-O-MHG              |

doi:10.1371/journal.pone.0156039.t001

Fig 4. MDA assay demonstrated increased lipid peroxidation in tolerant mice. Spinal cord extract from morphine group demonstrated a significant increase in MDA that was reduced by BPF (25 mg/kg) as well as by MnTBAP (10 mg/kg). Results are expressed as mean ± SEM for 15 rats. *P<0.001 vs Naive; †P<0.01 vs morphine.

doi:10.1371/journal.pone.0156039.g004
The development of morphine-induced tolerance is associated with tyrosine nitration and this is inhibited by BPF.

The development of morphine tolerance was associated with an increase of tyrosine-nitrated proteins in the L4-L5 portion of the dorsal horn such as the spinal glutamine synthetase (GS) (3±0.65 densitometric units for naïve group, 183.67±0.51 for morphine group; n = 5, P<0.001), an astrocytic enzyme that converts glutamate to its nontoxic analogue, glutamine [20]. The inhibition of antinociceptive tolerance by BPF was associated with an attenuation of posttranslational nitration of GS in the spinal cord (183.67±0.51 densitometric units for morphine group, 10.34±0.93 for morphine plus BPF; n = 5, P<0.001) (Fig 5A). Nitration of GS is shown by nitrotyrosine immunoprecipitation (Fig 5A). Glutamate levels were determined by HPLC in the spinal cord tissues. Total protein levels did not change among groups as measured by Western blotting analysis (Fig 5B).

| Sample                        | Amount of glutamate (μg/ml) |
|-------------------------------|-----------------------------|
| Naïve                         | 139 ± 0.52                  |
| Morphine                      | 170 ± 0.31                  |
| Morphine + BPF (25 mg/kg)     | 112 ± 0.23                  |

doi:10.1371/journal.pone.0156039.g005

Fig 5. Morphine antinociceptive tolerance is associated with nitrooxidative stress which is blocked by BPF. (A) When compared with naïve mice, morphine group lead to significant nitration of GS in the L4-L5 portion of the spinal cord tissues as measured by immunoprecipitation. Co-administration of morphine over 4 days with BPF (25 mg/kg) prevented GS nitration. Total protein levels did not change among groups as measured by Western blotting analysis. (B) Posttranslational nitration of GS led to functional enzymatic inactivation as evidenced by increased amount of glutamate. Co-administration of morphine with BPF (25 mg/kg) restored the enzymatic activity of GS. Gels shown are representative of gel results obtained from six animals and at least three experiments performed on different days. **P<0.001 vs Naïve; †††P<0.001 vs morphine.
these proteins is intimately linked to inactivation of their biological function. Indeed, amino acid HPLC analysis showed an increase of glutamate levels in morphine treated mice (Fig 5B), while BPF co-administration is able to restore basal glutamate level (Fig 5B). GS inactivation has important ramifications manifested by enhancing glutamatergic neurotransmission, which is key to central sensitization [21]. Therefore, our studies demonstrated that natural compounds with antioxidant activity are able to restore the analgesic efficacy of morphine via inhibition of free radicals agents, that are crucially for the cascade events induced by prolonged morphine administration.

**Discussion**

Opioid narcotics, such as the mainstay morphine, are the most effective treatments for acute and chronic severe pain but their clinical utility is nearly always hampered by the development of analgesic tolerance as well as painful hypersensitivity now known as morphine-induced hyperalgesia. Typically, the development of tolerance to morphine treatment necessitates escalating doses to achieve equivalent pain relief [22]. The underlying mechanisms are still poorly understood but several data associate nitroxidative stress to opioids tolerance and hyperalgesia [4, 23]. In particular, substantial evidence accumulated over the last years suggests that NMDA receptors and NO play an important role in the development of morphine tolerance [4, 5, 24]. Following repeated opioid administrations excessive excitation of the NMDA occurs indirectly via the activation of μ-opioid receptors. Activation of μ-receptor results, in turns, in indirect NMDA receptor activation by initiating a second-messenger PKC translocation to the membrane. In fact, PKC translocation activates the NMDA receptor by inducing the removal of Mg2+ blockade with consequent increased intracellular Ca2+ influx.

Increased iCa2+ leads to both activation of NO synthase followed by subsequent release of nitric oxide [25] and production of superoxide from mitochondria [26].

Simultaneous generation of these two molecules, SO and NO, favors the production of peroxynitrite, a very potent initiator of DNA strand breakage, which, in turn, initiates the production of the nuclear repair enzyme PARP. It was demonstrated that removal of SO and in turn of peroxynitrite inhibits poly-ADP-ribose-polymerase activation together with the inhibition of morphine tolerance [4, 14, 27].

In the present study, we decided to test for the first time, the efficacy of Bergamot Polyphe-nolic Portion (BPF) in this phenomena.

We observed that repeated administration of morphine for several consecutive days produced tolerance to the opioid and an increase in superoxide formation in the L4-L5 portion of the mice spinal cord. BPF co-administration was able to inhibit morphine antinociceptive tolerance reducing O2- chronic morphine-induced increase.

Epidemiological studies have shown that food has a direct impact on the health. In fact, plant derived foods such wine, fruits, nuts, vegetables, grains, legumes exert some beneficial effects on diseases [28]. The capacity of some plants to reduce the risk of chronic diseases is due to the presence of non-nutrient secondary metabolites, known phytochemicals, that exerts a wide range of biological activities. These metabolites include various groups of polyphenols (anthocyanins, flavones, isoflavones) and terpenoids (carotenoids, monoterpenes, and phytosterols). Their bioactivity has been associated to their antioxidant properties that are involved in the onset development of many of the chronic degenerative diseases such as cancer and inflammation [29, 30].

Recently, some studies have investigated the effect of some fruit’s and herb’s extracts as resveratrol, quercetin, curcumin, lycopene, myricitrin, genistein, and (-)-linalool on different experimental animal models of chronic pain [31–37].
An our recent study show that in a rodent model of opiate tolerance, removal of the free radicals with phenolic compounds of olive oil such as hydroxytyrosol and oleuropein re-instates the analgesic action of morphine. Chronic injection of morphine in mice led to the development of tolerance and this was associated with increased nitrotyrosine and MDA formation together with nitration and deactivation of MnSOD in the spinal cord. Removal of free radicals by hydroxytyrosol and oleuropein blocked morphine tolerance by inhibiting nitration and MDA formation and replacing the MnSOD activity. Thus, the analgesic effect in vivo of phenolic fraction of virgin olive oil derives from its antioxidant activities [38].

An excess of major pain neurotransmitter glutamate contributes to morphine hyperalgesia, in fact, stimulating NMDA receptors favors the maintenance of hyperalgesia via SO [5, 13] and NO formation [39, 40, 41, 25].

Removal of glutamate reduces the excitatory signals and prevents the persistence of excitotoxic levels of glutamate in the synaptic cleft. In the glial cells, glutamate is transformed in the non-toxic glutamine by the enzyme glutamine synthetase. Glutamine synthetase can be, in turn, inactivated by oxidation of one of the 16 histidine residues in the glutamine synthetase catalytic site [42] and nitration of GS tyrosine residues was also associated to morphine tolerance [4].

We observed that glutamate level seems to be associated to GS nitration. Furthermore, treatment of morphine-tolerant mice with BPF resulted in a reduction of SO production, MDA formation, prevention of GS nitration and re-establishment of glutamate levels leading to tolerance inhibition. These data highlight the importance of free radicals removal for the maintenance of the correct therapeutic function of opioid during pain state.

The use of natural antioxidant for the treatment of pain condition diseases, can be considered a new valid approach, effective and affordable, useful to control the disease development and progression. Natural products could be good remedy as they are better tolerated due to the less showed side effects.

Therefore, our translational research can constitute a new therapeutic approach for patients with chronic pain treatment and can help to improve their quality of life.

Author Contributions
Conceived and designed the experiments: C. Muscoli. Performed the experiments: FL SI LAG C. Morabito BMG CD. Analyzed the data: V. Malafoglia LAG MM MG. Contributed reagents/materials/analysis tools: V. Mollace WR. Wrote the paper: C. Muscoli FL.

References
1. Wang Y, Barker K, Shi S, Diaz M, Mo B, Gutstein HB. Blockade of PDGFR-[beta] activation eliminates morphine analgesic tolerance. Nature medicine 2012, 18(3), 385–387. doi: 10.1038/nm.2633 PMID: 22344297
2. Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain, Anticancer Drugs 1995, vol.6, suppl 3, pp. 4–13.
3. Li T, Hou Y, Cao W, Yan CX, Chen T, Li SB. Role of dopamine D3 receptors in basal nociception regulation and in morphine-induced tolerance and withdrawal. Brain research 2012, 1433, 80–84. doi: 10.1016/j.brainres.2011.11.045 PMID: 22154407
4. Muscoli C, Cuzzocrea S, Ndengele MM, Mollace V, Poreca F, Fabrizi F, et al. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. The Journal of clinical investigation 2007, 117(117 (11)), 3530–3539.
5. Muscoli C, Dagostino C, Ileri S, Lauro F, Gilozzi M, Bardhi E, et al. Posttranslational nitration of tyrosine residues modulates glutamate transmission and contributes to N-methyl-D-aspartate-mediated thermal hyperalgesia. Mediators of inflammation, 2013. doi: 10.1155/2013/950947
6. Salvemini D. Peroxynitrite and opiate antinociceptive tolerance: a painful reality, Arch. Biochem. Biophys. 2009, vol. 484, no. 2, pp. 238–44.
7. Mollace V, Sacco I, Janda E, Malara C, Ventrice D, Colica C, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 2011, 82(3), 309–316. doi: 10.1016/j.fitote.2010.01.014 PMID: 21056640

8. Mandalari G, Bennett RN, Bisignano G, Trombetta D, Saija A, Faulds CB, et al. Antimicrobial activity of flavonoids extracted from bergamot (Citrus bergamia Risso) peel, a byproduct of the essential oil industry. Journal of Applied Microbiology 2007, 103(6), 2056–2064. PMID: 18045389

9. Laird K, Phillips C. Vapour phase: a potential future use for essential oils as antimicrobials? Lett. Appl. Microbiol. 2012, vol. 54, no. 3, pp. 169–74.

10. Corasaniti MT, Maiuolo J, Maida S, Fratto V, Navarra M, Russo R, et al. Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. British journal of pharmacology 2007, 151(4), 518–529. PMID: 17401440

11. Mollace V, Ragusa S, Sacco I, Muscoli C, Sculco F, Visalli V, et al. The protective effect of bergamot oil extract on lecithin-like oxyLDL receptor-1 expression in balloon injury-related neointima formation. Journal of cardiovascular pharmacology and therapeutics 2008, 13(2), 120–129. doi: 10.1177/1074248407313821 PMID: 18413898

12. Wei A, Shibamoto T. Antioxidant/lipoxygenase inhibitory activities and chemical compositions of selected essential oils, J. Agric. Food. Chem. 2010, vol. 58, no. 12, pp. 7218–25.

13. Muscoli C, Mollace V, Wheatley J, Masini E, Ndengele M, Wang ZQ, et al. Superoxide-mediated nitration of spinal manganese superoxide dismutase: a novel pathway in N-methyl-D-aspartate-mediated hyperalgesia. Pain 2004, 111(1), 96–103.

14. Wang ZQ, Porreca F, Cuzzocrea S, Galen K, Lightfoot R, Masini E, et al. A newly identified role for superoxide in inflammatory pain. Journal of Pharmacology and Experimental Therapeutics 2004, 309(3), 869–878. PMID: 14988418

15. Takagi N, Logan R, Teves L, Wallace MC, Gurd JW. Altered Interaction Between PSD-95 and the NMDA Receptor Following Transient Global Ischemia. Journal of neurochemistry 2000, 74(1), 169–178. PMID: 10617118

16. Salerno R, Casale F, Calandruccio C, Procopio A. Characterization of flavonoids in Citrus bergamia (Bergamot) polyphenolic fraction by liquid chromatography–high resolution mass spectrometry (LC/HRMS)-Pharmanutrition-doi: 10.1016/j.phanu.2015.10.001

17. Warleta F, Quesada CS, Campos M, Allouche Y, Beltrán G, Gaforio JJ. Hydroxytyrosol protects against oxidative DNA damage in human breast cells. Nutrients 2011, 3(10), 839–857. doi: 10.3390/nu3100839 PMID: 22254082

18. Mattson MP. Involvement of superoxide in pathogenic action of mutations that cause Alzheimer's disease, Methods Enzymol. 2002, vol. 352, pp. 455–74.

19. Degli Esposti M. Measuring mitochondrial reactive oxygen species, Methods 2002, vol. 26, no. 4, pp. 335–40.

20. Dao DN, Ahdab-Barmada M, Schor NF. Cerellar glutamine synthetase in children after hypoxia or ischemia, Stroke 1991, vol. 22, no. 10, pp. 1312–6, 1991.

21. Muscoli C, Doyle T, Baggetto L, Bryant L, Chen Z, Watkins LR, et al. Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. The Journal of Neuroscience 2010, 30(46), 15400–15408. doi: 10.1523/JNEUROSCI.2391-10.2010 PMID: 21084596

22. Salvenini D, Little JW, Doyle T, Neumann WL. Roles of reactive oxygen and nitrogen species in pain. Free Radical Biology and Medicine 2011, 51(5), 951–966. doi: 10.1016/j.freeradbiomed.2011.01.026 PMID: 21277369

23. Wang ZQ, Porreca F, Cuzzocrea S, Galen K, Lightfoot R, Masini E, et al. A newly identified role for superoxide in inflammatory pain. Journal of Pharmacology and Experimental Therapeutics 2004, 309(3), 869–878. PMID: 14988418

24. Abdel-Zaher AO, Abdel-Rahman MS, ELwasei FM. Blockade of nitric oxide overproduction and oxidative stress by Nigella sativa oil attenuates morphine-induced tolerance and dependence in mice. Neurochemical research 2010, 35(10), 1557–1564. doi: 10.1007/s11064-010-0215-2 PMID: 20552271

25. Moller ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal cord, Pain. 1993, vol. 52, no. 2, pp. 127–36, 1993.

26. McInnis J, Wang C, Anastasio N, Hultman M, Ye Y, Salvenini D. The Role of Superoxide and Nuclear Factor-kB Signaling in N-Methyl-D-aspartate-Induced Necrosis and Apoptosis. Journal of Pharmacology and Experimental Therapeutics 2002, 301(2), 478–487. PMID: 11961046

27. Salvenini D, Muscoli C, Riley DP, Cuzzocrea S. Superoxide dismutase mimetics. Pulmonary pharmacology & therapeutics 2002, 15(5), 439–447.

28. Espín JC, García-Conesa MT, Tomás-Barberán FA. Nutraceuticals: facts and fiction, Phytochemistry. 2007, vol. 68, no. 22–24, pp. 2986–3008.
29. Manach C, Scalbert A, Morand C. Polyphenols: food sources and bioavailability, Am J Clin Nutr 2004, vol. 79, pp. 727–47.

30. Arts IC, Hollman PCH. Polyphenols and disease risk in epidemiologic studies, Am J Clin Nutr 2005, vol. 81, suppl, pp. 317S–25S.

31. Shao H, Xue Q, Zhang F, Luo Y, Zhu H, Zhang X, et al. Spinal SIRT1 Activation Attenuates Neuropathic Pain in Mice. PLoS One. 2014 Jun 24; 9(6):e100938. doi: 10.1371/journal.pone.0100938 eCollection 2014. PMID: 24959710

32. Raygude KS, Kandhare AD, Ghosh P, Ghule AE, Bodhankar SL. Evaluation of ameliorative effect of quercetin in experimental model of alcoholic neuropathy in rats. Inflammopharmacology 2012, 20(6), 331–341. doi: 10.1007/s10787-012-0122-z PMID: 22349996

33. Sharma S, Kulkarni SK, Agrewala JN, Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. European journal of pharmacology 2006, 536(3), 256–261. PMID: 16584726

34. Kuhad A, Chopra K. Lycopene ameliorates thermal hyperalgesia and cold allodynia in STZA-induced diabetic rat, Indian J Exp Biol. 2008, vol. 46, no. 2, pp. 108–11.

35. Meotti FC, Missau FC, Ferreira J, Pizzolatti MG, Mizuzaki C, Nogueira CW, et al. Anti-allodynic property of flavonoid myricitrin in models of persistent inflammatory and neuropathic pain in mice. Biochemical pharmacology 2006, 72(12), 1707–1713. PMID: 17070780

36. Valsecchi AE, Franchi S, Panerai AE, Sacerdote P, Trovato AE, et al. Genistein, a natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: anti-inflammatory and antioxidant activity. Journal of neurochemistry 2008, 107(1), 230–240. doi: 10.1111/j.1471-4159.2008.05614.x PMID: 18691380

37. Batista P. A., de Paula Werner M. F., Oliveira E. C., Burgos L., Pereira P., da Silva Brum L. F. et al., The antinociceptive effect of (-)-linalool in models of chronic inflammatory and neuropathic hypersensitivity in mice. The Journal of Pain 2010, 11(11), 1222–1229. doi: 10.1016/j.jpain.2010.02.022 PMID: 20452289

38. Muscoli C, Lauro F, Dagostino C, Ilii S, Giancotti LA, Giozzi M, et al. Olea Europea-derived phenolic products attenuate antinociceptive morphine tolerance: an innovative strategic approach to treat cancer pain. Journal of biological regulators and homeostatic agents 2013, 28(1), 105–116.

39. Fairbanks CA, Wilcox GL. Acute tolerance to spinally administered morphine compares mechanistically with chronically induced morphine tolerance, J. Pharmacol. Exp. Ther. 1997, vol. 282, no. 3, pp. 1408–17.

40. Kolesnikov YA, Pick CG, Pasternak GW. NG-nitro-L-arginine prevents morphine tolerance, Eur. J. Pharmacol. 1992, vol. 221, no. 2–3, pp. 399–400.

41. Kitto KF, Haley JE, Wilcox GL. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse, Neurosci. Lett. 1992, vol. 148, no. 1–2, pp. 1–5.

42. Levine RL. Oxidative modification of glutamine synthetase. II. C of the ascorbate model system, J. Biol. Chem. 1983, vol. 258, pp. 11828–11833.